Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.43 |
| ▸ | NCK1 | P16333 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1771905 | 1.00 | EGFR (0.60) | EGFRALDH1A1PIK3CDPIK3CAFGFR4 | |
| SCHEMBL28801910 | 0.98 | EGFR (0.58) | EGFRALDH1A1PIK3CDPIK3CAFGFR4 | |
| SCHEMBL15147835 | 0.86 | EGFR (0.55) | EGFRALDH1A1PIK3CDPIK3CAFGFR4 | |
| SCHEMBL3535171 | 0.85 | PIK3CA (0.61) | EGFRPIK3CDPIK3CAFGFR4TDO2 | |
| SCHEMBL1771615 | 0.83 | EGFR (0.60) | EGFRALDH1A1CYP1A2IMPDH2CYP2A6 | |
| SCHEMBL27941975 | 0.82 | EGFR (0.80) | EGFRALDH1A1PIK3CDPIK3CAFGFR4 | |
| SCHEMBL21499259 | 0.80 | EGFR (0.44) | EGFRALDH1A1PIK3CDPIK3CAFGFR4 | |
| SCHEMBL29804792 | 0.79 | PIK3CA (0.51) | EGFRPIK3CDPIK3CAFGFR4CYP2A6 | |
| SCHEMBL8644295 | 0.78 | PIK3CA (0.73) | EGFRPIK3CDPIK3CAFGFR4TDO2 | |
| SCHEMBL29804751 | 0.78 | PIK3CA (0.54) | EGFRPIK3CDPIK3CAFGFR4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101924-A1 | KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260102395-A1 | INHIBITING HISTONE DEACETYLASE 6 | EIKONIZO THERAPEUTICS, INC. (US) | 2026-04-16 | — | — | US | disclosed |
| CN-119504613-B | Coumarin derivative containing quinazoline unit as well as preparation method and application thereof | 江苏海洋大学 | 2026-02-27 | — | — | CN | disclosed |
| US-20250230166-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | US | disclosed |
| US-12286429-B2 | 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-29 | — | — | US | disclosed |
| CN-119504613-A | Novel coumarin derivative containing quinazoline unit, and preparation method and application thereof | 江苏海洋大学 | 2025-02-25 | — | — | CN | disclosed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| US-11993601-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV | 2024-05-28 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-11597728-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-07 | — | — | US | disclosed |
| US-20230064443-A1 | 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide Derivatives Useful As a Factor XIa Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-02 | — | — | US | disclosed |
| WO-2022241484-A2 | QUINAZOLINE DERIVATIVES TARGETING R(CCUG) REPEATS IN MYOTONIC DYSTROPHY TYPE 2 | UNIVERSITY OF FLORIDA RESEARCHFOUNDATION, INCORPORATED (US) | 2022-11-17 | — | — | WO | disclosed |
| US-20220315583-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | EGFR 1500/4885ALDH1A1 344/4885PIK3CD 855/4885 |
| US-12286429-B2 | 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors | F11, F12, F13A1 | EGFR 2991/4885ALDH1A1 2307/4885PIK3CD 1779/4885 |
| US-20250230166-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC11 | EGFR 3354/4885ALDH1A1 755/4885PIK3CD 2693/4885 |
| US-20260102395-A1 | INHIBITING HISTONE DEACETYLASE 6 | HDAC6, HDAC1, HDAC8 | EGFR 2282/4885ALDH1A1 1511/4885PIK3CD 3713/4885 |
| US-20230064443-A1 | 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide Derivatives Useful As a Factor XIa Inhibitors | F11, F12, F13A1 | EGFR 3047/4885ALDH1A1 2398/4885PIK3CD 2128/4885 |
| US-11993601-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | EGFR 1500/4885ALDH1A1 344/4885PIK3CD 855/4885 |
| US-11597728-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | EGFR 1500/4885ALDH1A1 344/4885PIK3CD 855/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | EGFR 1500/4885ALDH1A1 344/4885PIK3CD 855/4885 |
| US-20220315583-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | EGFR 1500/4885ALDH1A1 344/4885PIK3CD 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.